This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

22 Oct 2012

Report reveals large untapped market for rheumatoid arthritis drugs

There is a major need for new rheumatoid arthritis therapies with a high degree of safety and significant clinical and economic benefits, according to Frost & Sullivan.


The emergence of anti-tumour necrosis factor (anti-TNF) therapies has vastly improved the treatment of rheumatoid arthritis in recent years, but there is still a need for more effective therapies, a report has claimed.

Related News